Improving Clinical Trial Participant Prescreening With Artificial Intelligence (AI): A Comparison of the Results of AI-Assisted vs Standard Methods in 3 Oncology Trials.

Journal: Therapeutic innovation & regulatory science
Published Date:

Abstract

BACKGROUND: Delays in clinical trial enrollment and difficulties enrolling representative samples continue to vex sponsors, sites, and patient populations. Here we investigated use of an artificial intelligence-powered technology, Mendel.ai, as a means of overcoming bottlenecks and potential biases associated with standard patient prescreening processes in an oncology setting.

Authors

  • Denise Calaprice-Whitty
    Calaprice-Whitty Consulting, Inc., PO Box 2451, Blue Jay, CA, 92317, USA. denise@dcwhittyconsulting.com.
  • Karim Galil
    Mendel AI, San Jose, CA, USA.
  • Wael Salloum
    Mendel AI, San Jose, CA, USA.
  • Ashkon Zariv
    Mendel AI, San Jose, CA, USA.
  • Bernal Jimenez
    Mendel AI, San Jose, CA, USA.